[HTML][HTML] … p38α MAPK inhibitor suppresses brain proinflammatory cytokine up-regulation and attenuates synaptic dysfunction and behavioral deficits in an Alzheimer's …

L Munoz, HR Ranaivo, SM Roy, W Hu, JM Craft… - Journal of …, 2007 - Springer
… human amyloid-beta (Aβ) and other disease-relevant stressors. However, the vast majority
disorders. The goal of this study was to test the hypothesis that brain p38α MAPK is a …

[HTML][HTML] Recent advances in the inhibition of p38 MAPK as a potential strategy for the treatment of Alzheimer's disease

JK Lee, NJ Kim - Molecules, 2017 - mdpi.com
… p38 MAPK. More recently, Bhaskar’s group reported that a recently reported selective p38α
MAPK direct inhibitor 8 [78] suppresses p38α MAPK … impairment in aged hTau mice. Another …

Targeting p38 MAPK pathway for the treatment of Alzheimer's disease

L Munoz, AJ Ammit - Neuropharmacology, 2010 - Elsevier
… to develop selective inhibitors of p38α alone or both p38α and p38β for the … p38 MAPK is
exclusively localized in association with neurofibrillar pathology. Studies using transgenic mice

The p38 MAP kinase signaling pathway in Alzheimer's disease

GVW Johnson, CDC Bailey - Experimental neurology, 2003 - Elsevier
… In mice that were double transgenic for mutant amyloid precursor … the MAP kinase families,
the p38 family members are activated by upstream dual-specificity kinases called MAP kinase

Role of p38/MAPKs in Alzheimer's disease: implications for amyloid beta toxicity targeted therapy

G Kheiri, M Dolatshahi, F Rahmani… - Reviews in the …, 2018 - degruyter.com
… Treatment of old hTau mice with MW181 reduced activation of p38α MAPK and increased
expression of synaptophysin protein which resulted in improved working memory, supportive …

[HTML][HTML] Neuronal p38α mediates synaptic and cognitive dysfunction in an Alzheimer's mouse model by controlling β-amyloid production

S Colié, S Sarroca, R Palenzuela, I Garcia, A Matheu… - Scientific reports, 2017 - nature.com
… We crossed the p38α∆-N mice with 5XFAD mice expressing two transgenes with AD
clinical mutations, an early-onset AD mouse model 28 . Indeed, at 2–3 months of age, 5XFAD …

p38αMAPK‐deficient myeloid cells ameliorate symptoms and pathology of APP‐transgenic Alzheimer's disease mice

Q Luo, L Schnöder, W Hao, K Litzenburger… - Aging …, 2022 - Wiley Online Library
mice and inhibited by p38α-MAPK deficiency in myeloid cells in both early and late disease
… To further analyze the inflammatory activity of microglia in p38α-MAPK-deficient AD mice, we …

[HTML][HTML] Deficiency of neuronal p38α MAPK attenuates amyloid pathology in Alzheimer disease mouse and cell models through facilitating lysosomal degradation of …

L Schnöder, W Hao, Y Qin, S Liu, I Tomic, X Liu… - Journal of Biological …, 2016 - ASBMB
… In Alzheimer amyloid precursor protein-transgenic mice and … of mapk14, which encodes
p38α MAPK, a kinase sensitive to … that reduction of p38α MAPK expression facilitated the …

[HTML][HTML] Involvement of p38 MAPK in synaptic function and dysfunction

C Falcicchia, F Tozzi, O Arancio, DM Watterson… - International journal of …, 2020 - mdpi.com
… of Alzheimer’s disease (AD), … mice, suggesting that p38α MAPK plays a role in the process
of Aβ deposition in vivo [71]. Moreover, the selective pharmacological inhibition of p38α MAPK

Neuronal deficiency of p38α-MAPK ameliorates symptoms and pathology of APP or Tau-transgenic Alzheimer's mouse models

L Schnöder, G Gasparoni, K Nordström, A Schottek… - 2020 - jahrbib.sulb.uni-saarland.de
Alzheimer's disease (AD) is the leading cause of dementia with very limited therapeutic …
The cellular specificity of Cre-mediated p38α-MAPK deletion in neurons of APPtg mice